Diagnostic potential of circulating nucleic acids for oncology

Expert Review of Molecular Diagnostics

Volumn 3, Issue 4, 2003, Pages 431-442

  Goessl, Carsten ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cancer detection; Circulating nucleic acids in plasma and serum; Tumor DNA; Tumor RNA

Indexed keywords

NUCLEIC ACID; TUMOR MARKER;

AUTOMATION; BIOMEDICAL TECHNOLOGY ASSESSMENT; CANCER; CANCER DIAGNOSIS; CANCER SURVIVAL; DIAGNOSTIC VALUE; HUMAN; ONCOLOGY; PATIENT MONITORING; QUALITY OF LIFE; REVIEW; SENSITIVITY AND SPECIFICITY;

EID: 0037484740     PISSN: 14737159     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.3.4.431     Document Type: Review

References (103)

1. Sidransky D, Von Eschenbach A, Tsai YC et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 252, 706-709 (1991). First report of noninvasive DNA-based detection of human malignancy using body fluid material.
2. Steiner G, Schoenberg MP, Linn JF et al. Detection of bladder cancer recurrence by microsatellite analysis of urine. Nature Med. 3, 621-624 (1997). Demonstrates that molecular diagnosis can precede conventional diagnosis of bladder cancer recurrence.
3. Palmisano WA, Divine KK, Saccomanno G et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 60, 5954-5958 (2000).
4. Sidransky D. Emerging molecular markers of cancer. Nature Rev. Cancer 2, 210-219 (2002).
5. Ghossein RA, Bhattacharya S. Molecular detection and characterisation of circulating tumour cells and micrometastases in solid tumours. Eur. J. Cancer 36, 1681-1694 (2000).
6. Zippelius A, Pantel K. RT-PCR-based detection of occult disseminated tumor cells in peripheral blood and bone marrow of patients with solid tumors. An overview. Ann. NYA Acad. Sci. 906, 110-123 (2000).
7. Anker P, Mulcahy H, Stroun M. Circulating nucleic acids in plasma and serum as a noninvasive investigation for cancer: time for large-scale clinical studies? Int. J. Cancer 103, 149-152 (2003). Comprehensive overview on the potential of circulating nucleic acids in plasma and serum (CNAPS) analysis for oncology.
8. Johnson PJ, Lo YM. Plasma nucleic acids in the diagnosis and management of malignant disease. Clin. Chem. 48, 1186-1193 (2002).
9. Mandel P, Metais P. Les acides nucleiques du plasma sanguine chez l'homme. CR Acad. Sci. Paris 142, 241-243 (1948). First description of cell-free nucleic acid in human blood plasma.
10. Leon SA, Shapiro B, Sklaroff DM et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 37, 646-650 (1977).
11. Leon SA, Ehrlich GE, Shapiro B, Labbate VA. Free DNA in the serum of rheumatoid arthritis patients. J. Rheumatol. 4, 139-141 (1977).
12. Stroun M, Anker P, Maurice P et al. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 46, 318-322 (1989).
13. Stroun M, Anker P, Auderset G. Natural release of nucleic acids from bacteria into plant cells. Nature 227, 607-608 (1970).
14. Anker P, Stroun M, Maurice PA. Spontaneous release of DNA by human blood lymphoctyes as shown in an in vitro system. Cancer Res. 35, 2375-2382 (1975).
15. Sorenson GD, Pribish DM, Valone FH et al. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol. Biomarkers Prev. 3, 67-71 (1994).
16. Chen XQ, Stroun M, Magnenat JL et al. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nature Med. 2, 1033-1035 (1996).
17. Nawroz H, Koch W, Anker P et al. Microsatellite alterations in serum DNA of head and neck cancer patients. Nature Med. 2, 1035-1037 (1996).
18. Chan AK, Chiu RW, Lo YM. Cell-free nucleic acids in plasma, serum and urine: a new tool in molecular diagnosis. Ann. Clin. Biochem. 40(Pt 2), 122-130 (2003).
19. Lo YM, Chan LY, Lo KW et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res. 59, 1188-1191 (1999).
20. Kawakami K, Brabender J, Lord RV et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J. Natl Cancer Inst. 92, 1805-1811 (2000). First use of quantitative PCR techniques (methylation-specific PCR) for detecting tumor DNA in plasma/serum of cancer patients.
21. Usadel H, Brabender J, Danenberg KD et al. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum and plasma DNA of patients with lung cancer. Cancer Res. 62, 371-375 (2002).
22. Jeronimo C, Usadel H, Henrique R et al. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology 60, 1131-1135 (2002).
23. Wong IH, Zhang J, Lai PB et al. Quantitative analysis of tumor-derived methylated p 16INK4a sequences in plasma, serum and blood cells of hepatocellular carcinoma patients. Clin. Cancer Res. 9, 1047-1052 (2003).
24. Garcia-Olmo D, Garcia-Olmo DC, Ontanon J et al. Tumor DNA circulating in the plasma might play a role in metastasis. The hypothesis of the genometastasis. Histol Histopathol 14, 1159-1164 (1999). Describes horizontal gene transfer of circulating tumor DNA in an animal model raising the hypothesis that this phenomenon could be functionally involved in metastasis.
25. Garcia-Olmo D, Garcia-Olmo DC. Functionality of circulating DNA: the hypothesis of genometastasis. Ann. NY Acad. Sci. 945, 265-275 (2001).
26. Bergsmedh A, Szeles A, Henriksson M et al. Horizontal transfer of oncogenes by uptake of apoptotic bodies. Proc. Natl Acad. Sci. USA 98, 6407-6411 (2001).
27. Taback B, Giuliano AE, Hansen NM, Singer FR, Shu S, Hoon DSB. Detection of tumor-specific genetic alterations in bone marrow from early-stage breast cancer patients. Cancer Res. 63, 1884-1887 (2003).
28. Chiu RW, Poon LL, Lau TK et al. Effects of blood-processing protocols on fetal and total DNA quantification in maternal plasma. Clin. Chem. 47, 1607-1613 (2001).
29. Lee TH, Montalvo L, Chrebtow V et al. Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma. Transfusion 41, 276-282 (2001).
30. Thijssen MA, Swinkels DW, Ruers TJ et al. Difference between free circulating plasma and serum DNA in patients with colorectal liver metastases. Anticancer Res. 22(1A), 421-425 (2002).
31. Ziegler A, Zangemeister-Wittke U, Stahel RA. Circulating DNA: a new diagnostic gold mine? Cancer Treat. Rev. 28, 255-271 (2002).
32. Dixon SC, Horti J, Guo Y et al. Methods for extracting and amplifying genomic DNA isolated from frozen serum. Nature Biotechnol 16, 91-94 (1998). Thorough comparison of different methods for isolation of cell-free DNA from frozen serum specimens.
33. de Kok JB, Hendriks JC, van Solinge WW et al. Use of real-time quantitative PCR to compare DNA isolation methods. Clin. Chem. 44, 2201-2204 (1998).
34. Sozzi G, Conte D, Mariani L et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res. 61, 4675-4678 (2001).
35. Fournie GJ, Courtin JP, Laval F et al. Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours. Cancer Lett. 91, 221-227 (1995).
36. Jahr S, Hentze H, Englisch S et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 61, 1659-1665 (2001).
37. Hibi K, Robinson CR, Booker S. Molecular detection of genetic alterations in the serum of colorectal cancer patients. Cancer Res. 58, 1405-1407 (1998).
38. Goessl C, Heicappell R, Münker R et al. Microsatellite analysis of plasma DNA from patients with clear cell renal carcinoma. Cancer Res. 58, 4728-4732 (1998).
39. Stroun M, Lyautey J, Lederrey C et al. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin. Chim. Acta 313 (1-2), 139-142 (2001).
40. Botezatu I, Serdyuk O, Potapova G et al. Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism. Clin. Chem. 46(8 Pt 1), 1078-1084 (2000). Describes the recovery of tumor DNA from nonurological malignancies in urine, providing evidence that CNAPS of cancer patients may cross the renal barrier.
41. Lo YM. Molecular testing of urine: catching DNA on the way out. Clin. Chem. 46(8 Pt 1), 1039-1040 (2000).
42. Kopreski MS, Benko FA, Kwak LW et al. Detection of tumor messenger RNA in the serum of patients with malignant melanoma. Clin. Cancer Res. 5, 1961-1965 (1999). First demonstration of tumor RNA in serum of cancer patients.
43. Hasselmann DO, Rappl G, Rossler M et al. Detection of tumor-associated circulating mRNA in serum, plasma and blood cells from patients with disseminated malignant melanoma. Oncol. Rep. 8, 115-118 (2001).
44. Chen XQ, Bonnefoi H, Pelte MF et al. Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin. Cancer Res. 6, 3823-3836 (2000).
45. Silva JM, Dominguez G, Silva J et al. Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics. Clin. Cancer Res. 7, 2821-2825 (2001).
46. Silva J, Silva JM, Garcia V et al. RNA is more sensitive than DNA in identification of breast cancer patients bearing tumor nucleic acids in plasma. Genes Chromosomes Cancer 35, 375-376 (2002).
47. Silva JM, Rodriguez R, Garcia JM et al. Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells. Gut 50, 530-534 (2002).
48. Fleischhacker M, Beinert T, Ermitsch M et al. Detection of amplifiable messenger RNA in the serum of patients with lung cancer. Ann. NY Acad. Sci. 945, 179-188 (2001). Demonstrates the feasibility of tumor miniprofiling using serum RNA.
49. Hasselmann DO, Rappl G, Tilgen W et al. Extracellular tyrosinase tomuor RNA within apoptotic bodies is protected from degradation in human serum. Clin. Chem. 47, 1488-1489 (2001).
50. Garcia JM, Silva JM, Dominguez G et al. Heterogeneous tumor clones as an explanation of discordance between plasma DNA and tumor DNA alterations. Genes Chromosomes Cancer 31, 300-301 (2001).
51. Beau-Faller M, Gaub MP, Schneider A et al. Plasma DNA microsatellite panel as sensitive and tumor-specific marker in lung cancer patients. Int. J Cancer 105, 361-370 (2003).
52. Ryan BM, Lefort F, McManus R et al. A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow-up. Gut 52, 101-108 (2003).
53. Ramirez JL, Sarries C, de Castro PL et al. Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small cell lung cancer patients. Cancer Lett. 193, 207-216 (2003).
54. Kopreski MS, Benko FA, Borys DJ et al. Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA. J. Natl Cancer Inst. 92, 918-923 (2000). Describes k-ras mutations in the plasma of patients with colorectal cancer as well as adenoma (preinvasive tumor stage).
55. Fliss MS, Usadel H, Caballero OL et al. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 287, 2017-2019 (2000). First description of mitochondrial DNA mutations in body fluids of cancer patients.
56. Jeronimo C, Nomoto S, Caballero OL et al. Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene 20, 5195-5198 (2001).
57. Liu VW, Shi HH, Cheung AN et al. High incidence of somatic mitochondrial DNA mutations in human ovarian carcinomas. Cancer Res. 61, 5998-6001 (2001).
58. Hibi K, Nakayama H, Yamazaki T et al. Detection of mitochondrial DNA alterations in primary tumors and corresponding serum of colorectal cancer patients. Int. J. Cancer 94, 429-431 (2001).
59. Anker P, Lefort E Vasioukhin V et al. K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer. Gastroenterology 112, 1114-1120 (1997).
60. von Knobloch R, Hegele A, Brandt H et al. Serum DNA and urine DNA alterations of urinary transitional cell bladder carcinoma detected by fluorescent microsatellite analysis. Int. J. Cancer 94, 67-72 (2001).
61. Chen X, Bonnefoi H, Diebold-Berger S et al. Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer. Clin. Cancer Res. 5, 2297-2303 (1999).
62. Liu J, Zabarovska VI, Braga E et al. Loss of heterozygosity in tumor cells requires re-evaluation: the data are biased by the size-dependent differential sensitivity of allele detection. FEBS Lett. 462(1-2), 121-128 (1999). Methodical paper describing possible PCR amplification artifacts when using small amounts of DNA (such as those for CNAPS analysis).
63. Mayall F, Fairweather S, Wilkins R et al. Microsatellite abnormalities in plasma of patients with breast carcinoma: concordance with the primary tumour. J. Clin. Pathol. 52, 363-366 (1999).
64. Chang HW, Lee SM, Goodman SN et al. Assessment of plasma DNA levels, allelic imbalance and CA 125 as diagnostic tests for cancer. J. Natl Cancer Inst. 94, 1697-1703 (2002).
65. Belinsky SA, Palmisano WA, Gilliland FD et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res. 62, 2370-2377 (2002).
66. Laird PW. The power and the promise of DNA methylation markers. Nature Rev. Cancer 3, 253-266 (2003). Comprehensive review on gene promoter hypermethylation as a tumor marker focusing on application in body fluids.
67. Herman JG, Graff JR, Myohanen S et al. Methylation-specific PCP: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA 93, 9821-9826 (1996). First description of the method being used subsequently for detection of gene promoter hypermethylation in plasma/serum DNA of cancer patients.
68. Wong IH. Methylation profiling of human cancers in blood: molecular monitoring and prognostication (review). Int. J. Oncol 19, 1319-1324 (2001).
69. Goessl C. Noninvasive molecular detection of cancer - the bench and the bedside. Curr. Med. Chem. 10, 691-706 (2003).
70. Chan AT, Lo YM, Zee B et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J. Natl Cancer Inst. 94, 1614-1619 (2002).
71. Lei KI, Chan LY, Chan WY et al. Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma. Clin. Cancer Res. 8, 29-34 (2002).
72. Lo YM, Chan WY, Ng EK et al. Circulating Epstein-Barr virus DNA in the serum of patients with gastric carcinoma. Clin. Cancer Res. 7, 1856-1859 (2001).
73. Pornthanakasem W, Shotelersuk K, Termrungruanglert W et al. Human papillomavirus DNA in plasma of patients with cervical cancer. BMC Cancer 1, 2 (2001).
74. Dong SM, Pai SI, Rha SH et al. Detection and quantitation of human papillomavirus DNA in the plasma of patients with cervical carcinoma. Cancer Epidemiol. Biomarkers Prev. 11, 3-6 (2002).
75. Capone RB, Pai SI, Koch WM et al. Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma. Clin. Cancer Res. 6, 4171-4175 (2000).
76. Mulcahy HE, Lyautey J, Lederrey C et al. A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin. Cancer Res. 4, 271-275 (1998).
77. Gonzalez R, Silva JM, Sanchez A et al. Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients: follow-up study and prognostic significance. Ann. Oncol. 11, 1097-1104 (2000).
78. Kölble K, Ulrich OM, Pidde H et al. Microsatellite alterations in serum DNA of patients with colorectal cancer. Lab. Invest. 79, 1145-1150 (1999).
79. von Knobloch R, Hegele A, Brandt H et al. High frequency of serum DNA alterations in renal cell carcinoma detected by fluorescent microsatellite analysis. Int. J. Cancer 98, 889-894 (2002).
80. Fujiwara Y, Chi DD, Wang H et al. Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients. Cancer Res. 59, 1567-1571 (1999).
81. Shaw JA, Smith BM, Walsh T et al. Microsatellite alterations plasma DNA of primary breast cancer patients. Clin. Cancer Res. 6, 1119-1124 (2000).
82. Vasioukhin V, Anker P, Maurice Petal. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br. J. Haematol 86, 774-779 (1994).
83. Frickhofen N, Muller E, Sandherr M et al. Rearranged Ig heavy chain DNA is detectable in cell-free blood samples of patients with B-cell neoplasia. Blood 90, 4953-4960 (1997).
84. Jackson PE, Qian GS, Friesen M et al. Specific p53 mutations detected in plasma and tumors of hepatocellular carcinoma patients by electrospray ionization mass spectrometry. Cancer Res. 61, 33-35 (2001).
85. Esteller M, Sanchez-Cespedes M, Rosell R et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59, 67-70 (1999).
86. Silva JM, Dominguez G, Villanueva MJ et al. Aberrant DNA methylation of the p16INK4a gene in plasma DNA of breast cancer patients. Br. J. Cancer. 80, 1262-1264 (1999).
87. Sanchez-Cespedes M, Esteller M, Wu L et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res. 60, 892-895 (2000).
88. Goessl C, Krause H, Müller M et al. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res. 60, 5941-5945 (2000).
89. Nomoto S, Yamashita K, Koshikawa K et al. Mitochondrial D-loop mutations as clonal markers in multicentric hepatocellular carcinoma and plasma. Clin. Cancer Res. 8, 481-487 (2002).
90. Dasi F, Lledo S, Garcia-Granero E et al Real-time quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA: a simple blood test to monitor disease in cancer patients. Lab. Invest. 81, 767-769 (2001).
91. Mutirangura A, Pornthanakasem W, Theamboonlers A et al. Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma. Clin. Cancer Res. 4, 665-669 (1998). First description of the use of viral DNA for detection of virus-associated cancers in the Asia-Pacific region.
92. Lo KW, Lo YM, Leung SF et al. Analysis of cell-free Epstein-Barr virus associated RNA in the plasma of patients with nasopharyngeal carcinoma. Clin. Chem. 45 (8 Pt 1), 1292-1294 (1999).
93. Wright TC Jr, Cox JT, Massad LS et al. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 287, 2120-2129 (2002). Describes the incorporation of the molecular detection method into clinical guidelines for cervical cancer detection.
94. Wulfkuhle J, Liotta LA, Petricoin EF. Proteomic approaches for the early detection of cancer. Nature Rev. Cancer 3, 267-275 (2003).
95. Hartmann A, Moser K, Kriegmair M et al. Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. Am. J. Pathol. 154, 721-727 (1999). Describes integrated imaging (fluorescent cystoscopy), molecular (genetic alterations) and pathohistological approach for earlier detection of bladder cancer.
96. Mulshine JL. Screening for lung cancer: in pursuit of premetastatic disease. Nature Rev. Cancer 3, 65-73 (2003).
97. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002). Concludes that gene expression profiling of primary breast cancer better than any currently available clinical algorithm predicts which patient is at risk for recurrence and should therefore undergo adjuvant therapy. Similar findings from various other cancers reported in [98] demonstrate the generality of this approach.
98. Ramaswamy S, Ross KN, Lander ES et al. A molecular signature of metastasis in primary solid tumors. Nature Genet. 33, 49-54 (2003).
99. Barratt PL, Seymour MT, Stenning SP et al. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet 360, 1381-1391 (2002).
100. Esteller M, Garcia-Foncillas J, Andion E et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med 343, 1350-1354 (2000).
101. Balana C, Ramirez JL, Taron M et al. O(6)-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin. Cancer Res. 9, 1461-1468 (2003).
102. Buchholz TA, Stivers DN, Stec J et al. Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J. 8, 461-468 (2002).
103. Widschwendter M, Jones PA. The potential prognostic, predictive and therapeutic values of DNA methylation in cancer. Commentary re: Kwong J et al., promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin. Cancer Res. 8, 131-137 (2002). Comprehensive overview of the clinical potential of gene promoter hypermethylation analysis for oncology with a focus on noninvasive application in body fluids.